Neuro-oncology
EPCO-39. CLARIFYING THE MOLECULAR CONSEQUENCES OF ONCOGENIC MUTATIONS THROUGH MULTISCALE AND MULTIOMIC ANALYSIS OF INDIVIDUAL TUMORS.
Neuro-oncology
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Neuro-oncology
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Neuro-oncology
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
Neuro-oncology
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
Neuro-oncology